Oxford Nanopore Technologies Appoints Former Danaher Executive Francis Van Parys as New CEO
Cytiva
Cell and Gene Therapy CDMO
GE Healthcare
Digital Solution Provider
With Views, With Attitude
This is the Life Science Industry Observer Official Account's Issue #1505-3Period Article
Oxford Nanopore Technologies announced the appointment of Francis Van Parys as the new CEO.Francis will join the company's board of directors on March 2, 2026, as an executive director.
Francis has over 20 years of experience leading multi-billion-dollar life science enterprises, with an exceptional track record in scaling innovation-driven organizations through outstanding commercial and operational capabilities. He currently serves as the President and CEO of Radiometer, a global leader in acute care diagnostics and part of the Danaher Group (Danaher). Previously, Francis held senior leadership roles at Cytiva and GE Healthcare, driving sustained growth across Europe, Asia, and North America while building high-performing teams.
Francis Van Paris will succeed Gordon Sanghera, who has served as CEO since the founding of Oxford Nanopore in 2005. Gordon will step down from his board duties at the close of business on March 2, 2026, and will continue to serve as an advisor to the company until early 2027 to ensure a smooth transition.
With a new CEO, will ONT still seek to sell? The new CEO comes from Danaher. Is it possible for Danaher to acquire ONT?
❖ Disclaimer: The content of this article is for learning and communication purposes only. The views expressed are those of the author and do not necessarily represent those of the original author. For any questions, please contact the editor.
---The End---
Welcome to follow the official account by clicking
If you like it, just one-click triple action: like, favorite, and share.！